Nebraska Schedules

28-405. Controlled substances; schedules; enumerated. The following are the schedules of controlled
substances referred to in the Uniform Controlled Substances Act:

Schedule I


(a) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
unless specifically excepted, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific
chemical designation: (1) Acetylmethadol; (2) allylprodine; (3) alphacetylmethadol, except levo-alphacetylmethadol which is
also known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM; (4) alphameprodine; (5) alphamethadol; (6)
benzethidine; (7) betacetylmethadol; (8) betameprodine; (9) betamethadol; (10) betaprodine; (11) clonitazene; (12)
dextromoramide; (13) difenoxin; (14) diampromide; (15) diethylthiambutene; (16) dimenoxadol; (17) dimepheptanol; (18)
dimethylthiambutene; (19) dioxaphetyl butyrate; (20) dipipanone; (21) ethylmethylthiambutene; (22) etonitazene; (23)
etoxeridine; (24) furethidine; (25) hydroxypethidine; (26) ketobemidone; (27) levomoramide; (28) levophenacylmorphan;
(29) morpheridine; (30) noracymethadol; (31) norlevorphanol; (32) normethadone; (33) norpipanone; (34) phenadoxone;
(35) phenampromide; (36) phenomorphan; (37) phenoperidine; (38) piritramide; (39) proheptazine; (40) properidine; (41)
propiram; (42) racemoramide; (43) trimeperidine; (44) alpha-methylfentanyl,
N-(1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
(45) tilidine; (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N- phenylpropanamide, its optical and
geometric isomers, salts, and salts of isomers; (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers,
salts, and salts of isomers; (48) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts, and
salts of isomers; (49) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N- phenylacetamide (acetyl-alpha-methylfentanyl), its
optical isomers, salts, and salts of isomers; (50) N-(1-(1-methyl-2-(2-thienyl)ethyl-4-piperidyl)-N- phenylpropanamide
(alpha-methylthiofentanyl), its optical isomers, salts, and salts of isomers; (51)
N-(1-benxyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts, and salts of isomers; (52)
N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N- phenylpropanamide (beta-hydroxyfentanyl), its optical isomers, salts, and
salts of isomers; (53) N-(3-methyl-1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N- phenylpropanamide
(beta-hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers; (54)
N-(3-methyl-1-(2-(2-thienyl)ethyl-4-piperidyl)-N- phenylpropanamide (3-methylthiofentanyl), its optical and geometric
isomers, salts, and salts of isomers; (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N- phenylpropanamide (thenylfentanyl), its
optical isomers, salts, and salts of isomers; (56) N-(1-(2-(2-thienyl)ethyl-4-piperidyl)-N- phenylpropanamide (thiofentanyl),
its optical isomers, salts, and salts of isomers; and (57) N-(1-(2-phenylethyl) -4-piperidyl)-N-(4-fluorophenyl)-propanamide
(para-fluorofentanyl), its optical isomers, salts, and salts of isomers.

(b) Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted,
whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1)
Acetorphine; (2) acetyldihydrocodeine; (3) benzylmorphine; (4) codeine methylbromide; (5) codeine-N-Oxide; (6)
cyprenorphine; (7) desomorphine; (8) dihydromorphine; (9) drotebanol; (10) etorphine, except hydrochloride salt; (11)
heroin; (12) hydromorphinol; (13) methyldesorphine; (14) methyldihydromorphine; (15) morphine methylbromide; (16)
morphine methylsulfonate; (17) morphine-N-Oxide; (18) myrophine; (19) nicocodeine; (20) nicomorphine; (21)
normorphine; (22) pholcodine; and (23) thebacon.

(c) Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic
substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical designation, and, for purposes of this subdivision only,
isomer shall include the optical, position, and geometric isomers: (1) Bufotenine. Trade and other names shall include, but
are not limited to: 3-(B-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin;
5-hydroxy-N, N-dimethyltryptamine; and mappine; (2) diethyltryptamine. Trade and other names shall include, but are not
limited to: N, N-diethyltryptamine; and DET; (3) dimethyltryptamine. Trade and other names shall include, but are not
limited to: DMT; (4) 4-bromo-2, 5-dimethoxyamphetamine. Trade and other names shall include, but are not limited to:
4-bromo-2, 5-dimethoxy-a-methylphenethylamine; and 4-bromo-2, 5-DMA; (5) 4-methoxyamphetamine. Trade and other
names shall include, but are not limited to: 4-methoxy-a-methyl-phenethylamine; and paramethoxyamphetamine, PMA; (6)
4-methyl-2, 5-dimethoxyamphetamine. Trade and other names shall include, but are not limited to: 4-methyl-2,
5-dimethoxy-a-methylphenethylamine; DOM; and STP; (7) 5-methoxy-N-N, dimethyltryptamine; (8) ibogaine. Trade and
other names shall include, but are not limited to: 7-ethyl-6,6B,7,8,9,10,12,13-octahydro-2-methoxy-6, 9-methano-5H-pyrido
(1',2':1,2) azepino (5,4-b) indole; and tabernanthe iboga; (9) lysergic acid diethylamide; (10) marijuana; (11) mescaline; (12)
peyote. Peyote shall mean all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether
growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts,
derivative, mixture, or preparation of such plant or its seeds or extracts; (13) psilocybin; (14) psilocyn; (15)
tetrahydrocannabinols, including, but not limited to, synthetic equivalents of the substances contained in the plant or in the
resinous extractives of cannabis, sp. or synthetic substances, derivatives, and their isomers with similar chemical structure
and pharmacological activity such as the following: Delta 1 cis or trans tetrahydrocannabinol and their optical isomers,
excluding dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food
and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis or trans
tetrahydrocannabinol and its optical isomers. Since nomenclature of these substances is not internationally standardized,
compounds of these structures shall be included regardless of the numerical designation of atomic positions covered; (16)
3,4-methylenedioxy amphetamine; (17) 5-methoxy-3, 4-methylenedioxy amphetamine; (18) 3,4,5-trimethoxy amphetamine;
(19) N-ethyl-3-piperidyl benzilate; (20) N-methyl-3-peperidyl benzilate; (21) thiophene analog of phencyclidine. Trade and
other names shall include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienylanalog of phencyclidine;
TPCP; and TCP; (22) 2,5-dimethoxyamphetamine. Trade and other names shall include, but are not limited to:
2,5-dimethoxy-a-methylphenethylamine; and 2,5-DMA; (23) hashish or concentrated cannabis; (24) Parahexyl. Trade and
other names shall include, but are not limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,
9-trimethyl-6H-dibenzo(b,d)pyran; and synhexyl; (25) Ethylamine analog of phencyclidine. Trade and other names shall
include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine;
N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE; (26) Pyrrolidine analog of phencyclidine. Trade and other
names shall include, but are not limited to: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and PHP; (27)
3,4-methylenedioxymethamphetamine (MDMA), its optical, positional, and geometric isomers, salts, and salts of isomers;
and (28) Phenethylamine. Trade and other names shall include, but are not limited to:
4-bromo-2,5-dimethoxyphenethylamine; 2-CB; Venus; Bromo; Erox; and Nexus.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substances having a depressant effect on the central nervous system, including
its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within
the specific chemical designation: (1) Mecloqualone; and (2) methaqualone.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substances having a stimulant effect on the central nervous system, including
its salts, isomers, and salts of isomers: (1) Fenethylline; and (2) N-ethylamphetamine.

(f) Gamma hydroxy butyrate (GHB).

(g) Any controlled substance analogue to the extent intended for human consumption.

Schedule II


(a) Any of the following substances except those narcotic drugs listed in other schedules whether produced directly or
indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by
combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine,
buprenorphine, nalbuphine, nalmefene, naloxone, and naltrexone and their salts, but including the following: (i) Raw opium;
(ii) opium extracts; (iii) opium fluid extracts; (iv) powdered opium; (v) granulated opium; (vi) tincture of opium; (vii)
codeine; (viii) ethylmorphine; (ix) etorphine hydrochloride; (x) dihydrocodeinone which is also known as hydrocodone; (xi)
hydromorphone; (xii) metopon; (xiii) morphine; (xiv) oxycodone; (xv) oxymorphone; and (xvi) thebaine;

(2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent to or identical with any of the
substances referred to in subdivision (1) of this subdivision, except that these substances shall not include the isoquinoline
alkaloids of opium;

(3) Opium poppy and poppy straw;

(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative,
or preparation thereof which is chemically equivalent to or identical with any of these substances, including cocaine and its
salts, optical isomers, and salts of optical isomers, except that the substances shall not include decocainized coca leaves or
extractions which do not contain cocaine or ecgonine; and

(5) Concentrate of poppy straw, the crude extract of poppy straw in either liquid, solid, or powder form which contains
the phenanthrine alkaloids of the opium poppy.

(b) Unless specifically excepted or unless in another schedule any of the following opiates, including their isomers,
esters, ethers, salts, and salts of their isomers, esters, and ethers whenever the existence of such isomers, esters, ethers,
and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted: (1)
Alphaprodine; (2) anileridine; (3) bezitramide; (4) diphenoxylate; (5) fentanyl; (6) isomethadone; (7) levomethorphan; (8)
levorphanol; (9) metazocine; (10) methadone; (11) methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(12) moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid; (13) pethidine or meperidine;
(14) pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine; (15) pethidine-Intermediate-B,
ethyl-4-phenylpiperidine-4-carboxylate; (16) pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid; (17)
phenazocine; (18) piminodine; (19) racemethorphan; (20) racemorphan; (21) dihydrocodeine; (22) bulk dextropropoxyphene
in nondosage forms; (23) sufentanil; (24) alfentanil; and (25) levo-alphacetylmethadol which is also known as
levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM.

(c) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a
potential for abuse associated with a stimulant effect on the central nervous system: (1) Amphetamine, its salts, optical
isomers, and salts of its optical isomers; (2) phenmetrazine and its salts; (3) methamphetamine, its salts, isomers, and salts
of its isomers; and (4) methylphenidate.

(d) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a
potential for abuse associated with a depressant effect on the central nervous system, including their salts, isomers, and
salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical
designations: (1) Amobarbital; (2) secobarbital; (3) pentobarbital; (4) phencyclidine; and (5) glutethimide.

(e) Hallucinogenic substances known as: (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft gelatin
capsule in a Food and Drug Administration approved drug product. Some other names for dronabinol are
(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl- 3-pentyl-6H-dibenzo(b,d)pyran-1-o1 or
(-)-delta-9-(trans)-tetrahydrocannabinol; and (2) nabilone. Another name for nabilone is
(+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1- hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substances: (1) Immediate precursor to amphetamine and methamphetamine:
Phenylacetone. Trade and other names shall include, but are not limited to: Phenyl-2-propanone; P2P; benzyl methyl
ketone; and methyl benzyl ketone; or (2) immediate precursors to phencyclidine, PCP: (i) 1-phenylcyclohexylamine; or (ii)
1-piperidinocyclohexanecarbonitrile, PCC.

Schedule III


(a) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a
potential for abuse associated with a stimulant effect on the central nervous system, including their salts, isomers, whether
optical, position, or geometric, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation: (1) Benzphetamine; (2) chlorphentermine; (3) chlortermine; and (4)
phendimetrazine.

(b) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a
potential for abuse associated with a depressant effect on the central nervous system: (1) Any substance which contains
any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid, except those substances which
are specifically listed in other schedules of this section; (2) chlorhexadol; (3) lysergic acid; (4) lysergic acid amide; (5)
methyprylon; (6) sulfondiethylmethane; (7) sulfonethylmethane; (8) sulfonmethane; (9) nalorphine; (10) any compound,
mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt thereof and one or more other active
medicinal ingredients which are not listed in any schedule; (11) any suppository dosage form containing amobarbital,
secobarbital, pentobarbital, or any salt of any of these drugs and approved by the Food and Drug Administration for
marketing only as a suppository; and (12) tiletamine and zolazepam or any salt thereof. Trade or other names for a
tiletamine-zolazepam combination product shall include, but not be limited to: telazol. Trade or other names for tiletamine
shall include, but not be limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or other names for zolazepam shall
include, but not be limited to: 4-(2-fluorophenyl)-6, 8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and
flupyrazapon.

(c) Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs,
or any salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than one and eight-tenths grams of codeine per one hundred milliliters or not more than ninety milligrams
per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) Not more than one and eight-tenths grams of codeine per one hundred milliliters or not more than ninety milligrams
per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(3) Not more than three hundred milligrams of dihydrocodeinone which is also known as hydrocodone per one hundred
milliliters or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of
opium;

(4) Not more than three hundred milligrams of dihydrocodeinone which is also known as hydrocodone per one hundred
milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;

(5) Not more than one and eight-tenths grams of dihydrocodeine per one hundred milliliters or not more than ninety
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(6) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters or not more than fifteen
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(7) Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams, or not more
than twenty-five milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts; and

(8) Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams with one or more
active, nonnarcotic ingredients in recognized therapeutic amounts.

(d) Any anabolic steroid, which shall include any material, compound, mixture, or preparation containing any quantity of
the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is
possible within the specific chemical designation: (1) Boldenone; (2) chlorotestosterone (4-chlortestosterone); (3) clostebol;
(4) dehydrochlormethyltestosterone; (5) dihydrotestosterone (4-dihydrotestosterone); (6) drostanolone; (7) ethylestrenol; (8)
fluoxymesterone; (9) formebulone (formebolone); (10) mesterolone; (11) methandienone; (12) methandranone; (13)
methandriol; (14) methandrostenolone; (15) methenolone; (16) methyltestosterone; (17) mibolerone; (18) nandrolone; (19)
norethandrolone; (20) oxandrolone; (21) oxymesterone; (22) oxymetholone; (23) stanolone; (24) stanozolol; (25)
testolactone; (26) testosterone; (27) trenbolone; and (28) any salt, ester, or isomer of a drug or substance described or listed
in this subdivision if the salt, ester, or isomer promotes muscle growth.

Schedule IV


(a) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including
their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation: (1) Barbital; (2) chloral betaine; (3) chloral hydrate; (4) chlordiazepoxide, but not
including librax (chlordiazepoxide hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and water soluble
esterified estrogens); (5) clonazepam; (6) clorazepate; (7) diazepam; (8) ethchlorvynol; (9) ethinamate; (10) flurazepam;
(11) mebutamate; (12) meprobamate; (13) methohexital; (14) methylphenobarbital; (15) oxazepam; (16) paraldehyde; (17)
petrichloral; (18) phenobarbital; (19) prazepam; (20) alprazolam; (21) bromazepam; (22) camazepam; (23) clobazam; (24)
clotiazepam; (25) cloxazolam; (26) delorazepam; (27) estazolam; (28) ethyl loflazepate; (29) fludiazepam; (30)
flunitrazepam; (31) halazepam; (32) haloxazolam; (33) ketazolam; (34) loprazolam; (35) lorazepam; (36) lormetazepam;
(37) medazepam; (38) nimetazepam; (39) nitrazepam; (40) nordiazepam; (41) oxazolam; (42) pinazepam; (43) temazepam;
(44) tetrazepam; (45) triazolam; (46) midazolam; (47) quazepam; and (48) zolpidem.

(b) Any material, compound, mixture, or preparation which contains any quantity of the following substance, including
its salts, isomers, whether optical, position, or geometric, and salts of such isomers, whenever the existence of such salts,
isomers, and salts of isomers is possible: Fenfluramine.

(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substances having a stimulant effect on the central nervous system, including
their salts, isomers, whether optical, position, or geometric, and salts of such isomers whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical designation: (1) Diethylpropion; (2) phentermine; (3)
pemoline, including organometallic complexes and chelates thereof; (4) mazindol; (5) pipradrol; (6)
SPA,((-)-1-dimethylamino-1,2-diphenylethane); (7) cathine. Another name for cathine is ((+)-norpseudoephedrine); (8)
fencamfamin; (9) fenproporex; and (10) mefenorex.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following narcotic drugs, or their salts or isomers calculated as the free anhydrous base
or alkaloid, in limited quantities as set forth below: (1) Propoxyphene; and (2) not more than one milligram of difenoxin and
not less than twenty-five micrograms of atropine sulfate per dosage unit.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substance, including its salts: Pentazocine.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substance, including its salts, isomers, and salts of such isomers: Butorphanol.

(g)(1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substance, including its salts, optical isomers, and salts of such optical isomers:
Ephedrine.

(2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers are
excepted from subdivision (g)(1) of Schedule IV if they may lawfully be sold over the counter without a prescription under
the Federal Food, Drug, and Cosmetic Act; are labeled and marketed in a manner consistent with the pertinent OTC
Tentative Final or Final Monograph; are manufactured and distributed for legitimate medicinal use in a manner that reduces
or eliminates the likelihood of abuse; and are not marketed, advertised, or labeled for the indication of stimulation, mental
alertness, weight loss, muscle enhancement, appetite control, or energy:

(A) Solid oral dosage forms, including soft gelatin capsules, that combine active ingredients in the following ranges for
each dosage unit:

(i) Not less than one hundred milligrams nor more than one hundred thirty milligrams of theophylline and not less than
twelve and five-tenths milligrams nor more than twenty-four milligrams of ephedrine;

(ii) Not less than sixty milligrams nor more than one hundred milligrams of theophylline, not less than twelve and
five-tenths milligrams nor more than twenty-four milligrams of ephedrine, and not less than two hundred milligrams nor
more than four hundred milligrams of guaifenesin;

(iii) Not less than twelve and five-tenths milligrams nor more than twenty-five milligrams of ephedrine and not less than
two hundred milligrams nor more than four hundred milligrams of guaifenesin; and

(iv) Not more than eight milligrams of phenobarbital in combination with the ingredients of subdivision (g)(2)(A)(i) or
(g)(2)(A)(ii) of Schedule IV;

(B) Liquid oral dosage forms that combine active ingredients in the following ranges for each five-milliliter dose:

(i) Not more than forty-five milligrams of theophylline, not more than thirty-six milligrams of ephedrine, not more than
one hundred milligrams of guaifenesin, and not more than twelve milligrams of phenobarbital; and

(ii) Not more than five milligrams of phenylephrine, not more than five milligrams of ephedrine, not more than two
milligrams of chlorpheniramine, not more than ten milligrams of dextromethorphan, not more than forty milligrams of
ammonium chloride, and not more than five one-thousandths of a milligram of ipecac fluid extract; and

(C) Anorectal preparations containing less than five percent ephedrine.

Schedule V


(a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation
containing any of the following narcotic drug and its salts: (1) Buprenorphine.

(b) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts
calculated as the free anhydrous base or alkaloid, which shall include one or more nonnarcotic active medicinal ingredients
in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those
possessed by the narcotic drug alone:

(1) Not more than two hundred milligrams of codeine per one hundred milliliters or per one hundred grams;

(2) Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters or per one hundred grams;

(3) Not more than one hundred milligrams of ethylmorphine per one hundred milliliters or per one hundred grams;

(4) Not more than two and five-tenths milligrams of diphenoxylate and not less than twenty-five micrograms of atropine
sulfate per dosage unit;

(5) Not more than one hundred milligrams of opium per one hundred milliliters or per one hundred grams; and

(6) Not more than five-tenths milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per
dosage unit.


Source:


Laws 1977, LB 38, 65; Laws 1978, LB 748, 50; Laws 1980, LB 696, 2; Laws 1985, LB 323, 2;
Laws 1985, LB 406, 3; Laws 1986, LB 1160, 1; Laws 1987, LB 473, 1; Laws 1990, LB 571, 6;
Laws 1992, LB 1019, 32; Laws 1994, LB 1210, 3; Laws 1995, LB 406, 5; Laws 1996, LB 1213,
4; Laws 1998, LB 1073, 8; Laws 1999, LB 594, 1.
Operative date May 26, 1999.


Annotations:



An information containing the descriptive language from this section is not deficient if it contains an
incorrect trade name description, since the use of said language is unnecessary to constitute a proper charge
and is mere surplusage. State v. Spiegel, 239 Neb. 233, 474 N.W.2d 873 (1991).
Under subsections (c)(10) and (c)(15) of this section and section 28-404, marijuana is a Schedule I
controlled substance, and thus is a "drug." State v. Finnegan, 232 Neb. 75, 439 N.W.2d 496 (1989).